HAS2 and hepatocellular carcinoma: In vivo studies have shown that genetic or pharmacologic inhibition of HAS2 reduces stromal HA levels, alters the immune landscape, and significantly attenuates HCC growth, underscoring the HAS2-HA axis as a promising therapeutic target in liver cancer [103].